ABx Group (ASX:ABX) pegs ALCORE hydrogen fluoride at US$1,000/t

A 30-60% operating margin on a chemical Australia stopped making in 1995 reframes the ABx story

ABx Group (ASX:ABX) has released an indicative economic assessment for its ALCORE process that puts hydrogen fluoride production costs at US$1,000 to US$1,600 per tonne. Against current AHF prices of roughly US$2,400 per tonne in Europe, that implies an operating margin of 30 to 60%.

The number that matters is the comparison. The traditional acidspar route sits at roughly US$2,000 per tonne on today’s inputs and US$2,700 per tonne if 2030 fluorspar price forecasts prove correct. ALCORE, on the same assumptions, undercuts by US$400 to US$1,900 per tonne.

For a company most investors still slot into the rare earths bucket after last year’s 86% extraction results at Deep Leads, this is a useful reminder that ABx runs three quite different projects. ALCORE is the one that just got a proper commercial framing.

The context helps. Australia has imported 100% of its hydrogen fluoride since 1995 and fluorspar is now a critical mineral in five jurisdictions. China controls 79% of global acidspar and has cut exports by 80% since 2010.

Why the cost gap is bigger than it first looks

The ALCORE process uses aluminium smelter bath as feedstock rather than acidspar. Bath is a by-product from aluminium smelters that increasingly has nowhere to go, so ABx can source it cheaply while smelters avoid landfill costs.

That flips the raw material equation. Acidspar sits at US$520 per tonne today and is forecast to hit US$900 per tonne by 2030 as Chinese exports keep tightening. Bath is essentially a waste stream looking for a buyer.

The margin sensitivity works in ABx’s favour on two axes. If AHF prices hold, ALCORE captures the spread. If acidspar prices climb as forecast, competitors get squeezed while ALCORE’s economics stay intact.

The pilot plant is the number that has to work next

The economics assume a 20,000 tonne per year commercial plant. ABx has run the process at batch pilot scale and is now building a continuous pilot at Bell Bay in Tasmania, adjacent to the Rio Tinto aluminium smelter that supplies the bath.

The continuous pilot has to do two things. Confirm reactor designs and process conditions for commercial scale, and produce saleable AHF that customers can actually evaluate. Until that second step happens, offtake conversations stay hypothetical.

We think this is the honest risk. The economics look compelling on paper, but a batch pilot and an indicative operating cost estimate are not the same as a bankable feasibility study. Investors should treat the 30 to 60% margin as the prize, not the proof.

Where ALCORE fits inside the broader ABx story

ABx now has three quite separate stories running in parallel. The Deep Leads rare earths project delivered 86% extraction rates last year and has a Ucore offtake pathway. The bauxite business is generating cash through the Good Importing agreements. ALCORE is the longer-dated industrial chemicals bet.

The market has largely priced ABx as a rare earths developer with optionality. Today’s release nudges ALCORE from optionality toward something more concrete, though it stops well short of a funded commercial project.

The strategic pitch to Canberra almost writes itself. Domestic fluorine chemistry underpins lithium batteries, semiconductors, solar-grade quartz and aluminium smelting itself. A local AHF source addresses a gap that has existed since 1995.

The Investors Takeaway for ABx Group

The 30 to 60% operating margin headline is the kind of number that gets institutional investors interested in a small-cap industrial story. Whether it holds through a bankable feasibility, offtake agreements and a construction decision is the actual test.

Our take is that ABx has just given the market a reason to value ALCORE as more than a science project, but the re-rate needs the continuous pilot to produce saleable AHF and at least one customer signing something binding. Everything before that is still narrative. Investors can find our prior coverage of ABx and the Deep Leads rare earths results at stocksdownunder.

The next 12 months should tell us whether ALCORE is a genuine second leg to the ABx story or whether the market keeps treating it as an interesting side project attached to a rare earths developer.